Old Drugs, New Cures Act

This bill would allow makers of certain older drugs to avoid paying special rebates that they normally owe to Medicaid and Medicare. Right now, when a company creates a new version of an existing drug, like an extended-release form, they have to pay extra rebates to these government health programs. Under this bill, a drug company could skip those extra rebates if the drug has been approved for at least 10 years, the company is researching a new use for the drug that fills an important medical need, and that new use would help treat a disease or condition that is common among people covered by Medicaid, Medicare, or other federal health programs.

Your Vote